Novel Estrogen Receptor – Targeted Therapies in Hormone-Receptor Positive Breast Cancer

Article / By

The research discusses the evolving landscape of treatment for hormone-receptor positive metastatic breast cancer (HR+/HER2-) with a focus on novel endocrine-based therapies, particularly the use of CDK4/6 inhibitors as first-line treatment. It highlights the importance of molecular profiling to guide therapy selection after resistance develops, recommending specific treatments based on mutations and emphasizing the anticipated FDA approvals for new selective estrogen receptor degraders (SERDs) to enhance treatment options.

Novel Estrogen Receptor – Targeted Therapies in Hormone-Receptor Positive Breast Cancer Read More »

Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer

Article / By

This paper discusses the use of CDK4/6 inhibitors, specifically abemaciclib and ribociclib, in the adjuvant treatment of hormone-receptor-positive, HER2-negative early breast cancer, highlighting their efficacy in reducing recurrence rates when combined with endocrine therapy. It emphasizes the importance of patient selection, management of adverse events, and strategies to improve medication adherence, while also noting the ongoing research that aims to refine treatment approaches and enhance patient outcomes.

Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer Read More »

Application of Bone-Targeted Nanoparticles for Trilaciclib Delivery in Chemotherapy-Induced Myelosuppression

Article / By

The research discusses the use of bone-targeted PLGA-PEG nanoparticles functionalized with Alendronate for delivering Trilaciclib, an FDA-approved CDK4/6 inhibitor, to mitigate chemotherapy-induced myelosuppression. This targeted delivery aims to enhance drug specificity and reduce systemic toxicity, although it raises concerns about medication-related osteonecrosis of the jaw (MRONJ). The paper evaluates the feasibility and potential impact of this approach on improving chemotherapy outcomes.

Application of Bone-Targeted Nanoparticles for Trilaciclib Delivery in Chemotherapy-Induced Myelosuppression Read More »

Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers

Article / By

The research investigates how immune interactions within the tumor microenvironment contribute to resistance against the CDK4/6 inhibitor ribociclib in high-risk estrogen receptor-positive breast cancers undergoing endocrine therapy. Findings reveal that cancer cells promote immune suppression by altering myeloid cell differentiation and reducing T-cell activation, while exogenous IL-15 enhances the efficacy of ribociclib by boosting T-cell activity.

Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers Read More »

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer

Article / By

This study assesses the effectiveness and safety of CDK4/6 inhibitors in treating hormone receptor-positive breast cancer through a meta-analysis of 13 studies. The findings indicate that combining CDK4/6 inhibitors with endocrine therapy significantly improves progression-free survival and overall survival, although it may also lead to adverse drug reactions related to the blood and digestive systems.

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer Read More »

Association between body composition parameters and treatment-related toxicities in patients with metastatic breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors

Article / By

This study evaluated the relationship between body composition changes and treatment-related toxicities in metastatic breast cancer patients receiving CDK4/6 inhibitors. It found that while changes in muscularity and adiposity were associated with toxicities, dose reductions, and treatment discontinuation, the direction of these changes was not consistent. Notably, higher baseline skeletal muscle mass correlated with fewer severe adverse events.

Association between body composition parameters and treatment-related toxicities in patients with metastatic breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors Read More »

Impact of social support on body image during chemotherapy in patients with breast cancer: The chain mediating role of depression and self-efficacy

Article / By

The research explores how social support influences body image in breast cancer patients undergoing chemotherapy, highlighting the mediating roles of depression and self-efficacy. Findings indicate that social support is linked to lower depression and better self-efficacy, which in turn positively affects body image. The study suggests that enhancing social support and addressing depression and self-efficacy through psychological interventions can improve body image during treatment.

Impact of social support on body image during chemotherapy in patients with breast cancer: The chain mediating role of depression and self-efficacy Read More »

Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer

Article / By

The research identifies key clinical and gene expression features associated with progression-free survival (PFS) in patients with HR+/HER2− metastatic breast cancer receiving CDK4/6 inhibitor therapy. Significant factors influencing PFS include visceral disease, prior endocrine therapy, and the type of endocrine therapy used. The study also develops a predictive model based on these features, highlighting common gene networks related to cell cycle and estrogen receptor signaling.

Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer Read More »

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

Article / By

This Phase I trial evaluated the combination of ribociclib (a CDK4/6 inhibitor) and spartalizumab (a PD-1 inhibitor) with and without fulvestrant in patients with metastatic hormone receptor-positive breast cancer or advanced ovarian cancer. The study found that while the recommended phase 2 dose of ribociclib was established at 600 mg, the treatment showed limited efficacy and increased hepatotoxicity, leading to the conclusion that further development is not warranted.

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer Read More »

Valuable predictive power of prognostic nutritional index in metastatic breast cancer patients treated with CDK4/6 inhibitors

Article / By

The study investigates the prognostic value of the prognostic nutritional index (PNI) in HR+/HER2- metastatic breast cancer patients undergoing treatment with CDK4/6 inhibitors and endocrine therapy. Results indicate that patients with low PNI have significantly shorter progression-free and overall survival compared to those with high PNI, suggesting that PNI is a reliable indicator of prognosis in this patient population.

Valuable predictive power of prognostic nutritional index in metastatic breast cancer patients treated with CDK4/6 inhibitors Read More »

Start typing and press enter to search

This site is only for use by healthcare professionals.

By continuing to view this site you are confirming that you are a healthcare professional.

Confirm